|
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
October 2, 2023
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
|
Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer
|
March 19, 2024
|
PC3I Authors Ronac Mamtani |
Urologic Oncology
|
|
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
|
October 18, 2023
|
PC3I Authors Ronac Mamtani |
Frontiers in Oncology
|
|
A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes
|
January 20, 2021
|
PC3I Authors Ronac Mamtani |
European Journal of Gastroenterology & Hepatology
|
|
The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer
|
November 21, 2023
|
PC3I Authors Peter Gabriel; Ronac Mamtani |
Cancer
|
|
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy
|
June 16, 2021
|
PC3I Authors Peter Gabriel; Ronac Mamtani |
JCO Oncology Practice
|
|
Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
|
November 27, 2023
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis
|
September 22, 2021
|
PC3I Authors Ronac Mamtani |
Arthritis Care and Research (Hoboken)
|
|
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
January 19, 2024
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
|
Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer
|
October 6, 2021
|
PC3I Authors Samuel Takvorian; Daniel Lee; Roger Kim; Ronac Mamtani; Larry Shulman; William Ferrell; Caleb M. Hearn |
medRxiv
|
|
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
|
February 28, 2024
|
PC3I Authors Ronac Mamtani |
European Urology
|
|
Immunotherapy Adverse Effects
|
October 28, 2021
|
PC3I Authors Ronac Mamtani |
JAMA Oncology
|
|
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
|
March 12, 2024
|
PC3I Authors Ronac Mamtani |
Journal of Medical Economics
|
|
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers
|
November 4, 2021
|
PC3I Authors Ronac Mamtani |
JAMA Oncology
|
|
Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights
|
November 10, 2021
|
PC3I Authors Ronac Mamtani |
Journal of Biopharmaceutical Statistics
|
|
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States
|
December 11, 2021
|
PC3I Authors Samuel Takvorian; Daniel Lee; Roger Kim; Caleb M. Hearn; William Ferrell; Larry Shulman; Ronac Mamtani |
Journal of the National Cancer Institute
|
|
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
|
January 5, 2022
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma
|
January 23, 2022
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research and Clinical Oncology
|
|
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy
|
January 30, 2022
|
PC3I Authors Melina Marmarelis; Ronac Mamtani; Charu Aggarwal |
Clinical Lung Cancer
|
